Immunis, Inc., a clinical-stage biotech developing multi-active biologics for age and disease-related immune dysregulation, announces that it has initiated treatment in several patients of its STEM-META Phase 2 clinical trial. The Phase 2 trial will assess the safety and tolerability of Immunis’ investigational therapy, IMM01-STEM, in older patients with sarcopenia (muscle atrophy) related to obesity. The data from this trial will build upon the company’s Phase 1/2a trial investigating IMM01-STEM in adults with sarcopenia associated with knee osteoarthritis.

Aging heralds a progressive decline in immune system function, resulting in a cascade of degenerative conditions, including sarcopenia. Sarcopenia will occur in 100% of individuals as they age, yet there is no pharmaceutical treatment to attenuate muscle loss or enhance muscle regeneration. Additionally, muscle loss is highly correlated with comorbidities such as obesity, which can severely diminish quality of life.

“IMM01-STEM represents a paradigm shift in approaching age-related diseases like sarcopenic obesity, which involves both metabolic and inflammatory dysfunction,” states Erin Curry, PA-C, MPH, Director of Medical Affairs at Immunis.

IMM01-STEM is a novel, investigational secretome comprised of natural immunomodulators. Immunis’ groundbreaking multi-active biologic offers a multifaceted approach to combating these deleterious effects of aging.

“The published preclinical studies of IMM01-STEM in GeroScience and Aging Cell, have yielded a treasure trove of potential clinical applications and we are eager to explore how these data translate to humans,” adds Curry.

The Phase 2 study has five clinical sites that are actively recruiting patients. These sites include Hoag Orthopedics in Irvine and the National Institutes of Clinical Research (NICR) in Garden Grove and Pomona, California. Additionally, there are two more clinical sites open in Kansas at Johnson County Clinical Trials (JCCT) in Kansas City and Tekton Research in Wichita.

About Immunis Inc.

Immunis is a clinical-stage biotechnology company developing multi-active biologics for the various manifestations of age-related diseases and immune dysregulation. The investigational product line leverages Immunis’ leading-edge capabilities in stem cell-derived secretome technology to deliver a product of all natural, all human immune modulators in their natural physiological concentrations.

For additional information about Immunis’ programs, please visit our Pipeline.

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.

Contact email: contact@immunisbiomedical.com